• Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
  • Log In
    • Register
Contacts us @ MediPr.org
Medical News Asia | Powered by ['mediPr]
  • MDnews
  • About [‘mediPr]
  • HER2 Explorer
  • TROP Tool
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Tag Archive for: prostate cancer

Identifying-and-Managing-nmCRPC-Patients-in-the-Era-of-PSMA-PET-Imaging

Identifying and Managing nmCRPC Patients in the Era of PSMA-PET Imaging

7 December 2021/in Genitourinary Cancer, Oncology, Endocrine Therapy/by Kirsty LEE

There is no excerpt because this is a protected post.

Read more
https://medi-paper.com/wp-content/uploads/2021/12/Identifying-and-Managing-nmCRPC-Patients-in-the-Era-of-PSMA-PET-Imaging.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-12-07 09:56:442022-02-19 04:39:30Identifying and Managing nmCRPC Patients in the Era of PSMA-PET Imaging
Emerging options for the treatment of metastatic hormone-sensitive prostate cancer

Emerging options for the treatment of metastatic hormone-sensitive prostate cancer

23 April 2021/in Genitourinary Cancer, Oncology, Endocrine Therapy/by Kirsty LEE

There is no excerpt because this is a protected post.

Read more
https://medi-paper.com/wp-content/uploads/2021/04/Emerging-options-for-the-treatment-of-metastatic-hormone-sensitive-prostate-cancer.jpg 1024 1917 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2021-04-23 16:41:102022-07-13 05:56:36Emerging options for the treatment of metastatic hormone-sensitive prostate cancer
detecting-metastases-with-psma-pet-in-prostate-cancer

Detecting metastases with PSMA-PET in prostate cancer

8 December 2020/1 Comment/in Genitourinary Cancer, Oncology, Surgery and Procedures, Targeted Therapies/by Kirsty LEE

Conventional imaging with computed tomography (CT), magnetic resonance imaging (MRI) and bone scans, are the current standard of care for imaging prostate cancer. Accurate imaging primarily relies on nodal metastases size for detection.

Read more
https://medi-paper.com/wp-content/uploads/2020/12/detecting-metastases-with-psma-pet-in-prostate-cancer.jpg 1024 1819 Kirsty LEE https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png Kirsty LEE2020-12-08 10:03:172022-02-23 11:26:52Detecting metastases with PSMA-PET in prostate cancer

First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

22 August 2018/0 Comments/in Breast Cancer, Medical News Asia, Genitourinary Cancer, Lung Cancer, Oncology, Melanoma & Skin Cancer, Immunotherapy, Translational Research/by scienterrific

Biosceptre has announced the initiation of its Phase 1 clinical study with the peptide vaccine BIL06v. BIL06v is a peptide-protein conjugate that recruits the patient’s immune system to make antibodies specifically targeted at nfP2X7-expressing cancer cells resulting in tumour cell death.

Read more
0 0 scienterrific https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png scienterrific2018-08-22 11:48:172018-08-22 11:48:17First-in-Class Oncology Vaccine BIL06v Starts Phase 1 Evaluation

Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)

17 July 2018/0 Comments/in Genitourinary Cancer, US FDA Onc\Haem Approvals, Oncology, Endocrine Therapy/by scienterrific

On July 13, the FDA approved enzalutamide (Xtandi©, Astellas), for use in patients with castration-resistant prostate cancer (CRPC).

Read more
0 0 scienterrific https://medi-paper.com/wp-content/uploads/2020/02/MediPR-MediPaper-Medical-Communications-Ltd-Healthcare-Writers-Medical-Writers-Medical-Writer-Agency-Hong-Kong-Medical-Writing-Services-Solutions-Quote-醫學寫作-香港-醫學作家香港-medical-PR-public-relations-1030x374.png scienterrific2018-07-17 10:14:112018-07-17 10:14:11Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)

Categories

Categories

Newsletter


 [‘mediPr] | MediPaper Healthcare Writers | Digital Medical Marketing | Medical Writing Solutions 醫學寫作 | Medical Writing Quote | Medical Writing Portfolio | Medical Writer Hong Kong 醫學作家香港 | Hire Healthcare Writers Hong Kong | Contact our Medical Writer Agency | MediPaper Health News | CORTiX AI for Medical Science | Dub-Dub Subtitle Generation
© 2016-2026 MediPaper Medical Communications Ltd. | Website by [’mediPr] Sydney | Singapore | Hong Kong | 醫學作家香港 | Privacy Policy | Cookie Policy
  • Link to Facebook
  • Link to LinkedIn
  • Link to X
  • Link to Instagram
  • Link to Youtube
  • Link to Mail
  • Link to Rss this site
Scroll to top Scroll to top Scroll to top

This site uses cookies to improve your experience. By continuing to browse the site, you are agreeing to our use of cookies.

OKPrivacy Settings×

Cookies and Privacy on medi-paper.com



Cookie Policy

How MediPaper uses cookies is explained in our Cookie Policy

Privacy Policy

Read MediPaper's Privacy Policy

Google Analytics cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visist to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Vimeo and Youtube video embeds:

5
Accept settingsHide notification only